Effect of cimetidine on T lymphocytes in a patient with giant benign gastric ulcer
Related Experiment Video
Updated: Oct 8, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Abstract:
In view of the findings that Cimetidine, used in the treatment of gastric ulcers, blocks histamine-type 2 receptors, which are also present on T suppressor lymphocytes, a study was carried out in a 65-year-old male suffering from giant benign gastric ulcer and in parallel for control purposes in a healthy male of the same age. T suppressor cells obtained from peripheral blood of the patient were tested prior to institution of treatment with Cimetidine and 21, 62 and 100 days thereafter using 3 different tests - theophylline sensitivity, monoclonal antibodies OKT4 and OKT8 and as a functional test a local xenogeneic graft-versus-host reaction (GVHR). The number and percentage of T suppressor cells, which were high before treatment, showed a significant decrease after two months of treatment and this was paralleled by a decrease in suppressor activity and reversal of the functional activity of the T cells from negative to normal. Helper cells were normal before and after treatment. At the same time the patient showed a marked clinical improvement, with healing of the ulcer evidenced by endoscopy. It is suggested that Cimetidine may effect healing by influencing immune mechanisms.
More Related Videos
03:48Effects of Desmodium caudatum on Gastrointestinal Hormones and Intestinal Flora in Rats with Gastritis
Published on: March 1, 2024
03:05Establishment and Evaluation of a Risk Prediction Model for Pathological Escalation of Gastric Low-Grade Intraepithelial Neoplasia
Published on: February 16, 2024
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Injurious Factors
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds to M3...
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Gastritis II: Pathophysiology